Characteristics and predictors of long-term institutionalization in patients with schizophrenia

Schizophrenia Research

Volumn 131, Issue 1-3, 2011, Pages 120-126

  Uggerby, Peter ^a   Nielsen, René Ernst ^a   Correll, Christoph U ^b,c   Nielsen, Jimmi ^a  

^a AALBORG UNIVERSITY HOSPITAL   (Denmark)

^b ZUCKER HILLSIDE HOSPITAL   (United States)

^c ALBERT EINSTEIN COLLEGE OF MEDICINE   (United States)

Author keywords

Clozapine; Institutionalization; Outcome; Predictors; Schizophrenia; Treatment resistant

Indexed keywords

NEUROLEPTIC AGENT;

ACADEMIC ACHIEVEMENT; ADULT; AGE; ARTICLE; COHORT ANALYSIS; CONTROLLED STUDY; DENMARK; DRUG MISUSE; DRUG USE; FEMALE; FOLLOW UP; GENDER; HEBEPHRENIA; HUMAN; INSTITUTIONALIZATION; INTERNATIONAL CLASSIFICATION OF DISEASES; LOGISTIC REGRESSION ANALYSIS; LONG TERM CARE; MAJOR CLINICAL STUDY; MALE; MENTAL PATIENT; NON INSULIN DEPENDENT DIABETES MELLITUS; ONSET AGE; OUTCOME ASSESSMENT; PENSION; POLYPHARMACY; PRIORITY JOURNAL; RETIREMENT; SCHIZOPHRENIA; SUICIDE;

AGED; ANTIPSYCHOTIC AGENTS; CLOZAPINE; COHORT STUDIES; DENMARK; DIABETES MELLITUS, TYPE 2; EDUCATIONAL STATUS; FEMALE; HUMANS; INSTITUTIONALIZATION; INTERNATIONAL CLASSIFICATION OF DISEASES; LOGISTIC MODELS; MALE; MIDDLE AGED; PREDICTIVE VALUE OF TESTS; RETROSPECTIVE STUDIES; RISK FACTORS; SCHIZOPHRENIA;

EID: 80051802169     PISSN: 09209964     EISSN: 15732509     Source Type: Journal    
DOI: 10.1016/j.schres.2011.03.001     Document Type: Article

References (51)

1. Allebeck P. The use of population based registers in psychiatric research. Acta Psychiatr. Scand. 2009, 120(5):386-391.
2. Atkins M., Burgess A., Bottomley C., Riccio M. Chlorpromazine equivalents: a consensus of opinion for both clinical and research applications. Psychiatr. Bull. 1997, 21(4):224-226.
3. Barr C.E., Mednick S.A., Munk-Jorgensen P. Exposure to influenza epidemics during gestation and adult schizophrenia. A 40-year study. Arch. Gen. Psychiatry 1990, 47(9):869-874.
4. Bertelsen M., Jeppesen P., Petersen L., Thorup A., Ohlenschlaeger J., Le Quach P., Ostergaard Christensen T., Krarup G., Jorgensen P., Nordentoft M. Course of illness in a sample of 265 patients with first-episode psychosis-five-year follow-up of the Danish OPUS trial. Schizophr. Res. 2009, 107(2-3):173-178.
5. Bock C., Bukh J.D., Vinberg M., Gether U., Kessing L.V. Validity of the diagnosis of a single depressive episode in a case register. Clin. Pract. Epidemiol. Ment. Health 2009, 5:4.
6. Brown S., Birtwistle J., Roe L., Thompson C. The unhealthy lifestyle of people with schizophrenia. Psychol. Med. 1999, 29(3):697-701.
7. Buchanan R.W., Kreyenbuhl J., Kelly D.L., Noel J.M., Boggs D.L., Fischer B.A., Himelhoch S., Fang B., Peterson E., Aquino P.R., Keller W. The 2009 schizophrenia PORT psychopharmacological treatment recommendations and summary statements. Schizophr. Bull. 2010, 36(1):71-93. Schizophrenia Patient Outcomes Research Team (PORT).
8. Cantor-Graae E., Nordstrom L.G., McNeil T.F. Substance abuse in schizophrenia: a review of the literature and a study of correlates in Sweden. Schizophr. Res. 2001, 48(1):69-82.
9. Cascella N.G., Schretlen D.J., Sawa A. Schizophrenia and epilepsy: is there a shared susceptibility?. Neurosci. Res. 2009, 63(4):227-235.
10. Cohen D., Correll C.U. Second-generation antipsychotic-associated diabetes mellitus and diabetic ketoacidosis: mechanisms, predictors, and screening need. J. Clin. Psychiatry 2009, 70(5):765-766.
11. Gaitatzis A., Trimble M.R., Sander J.W. The psychiatric comorbidity of epilepsy. Acta Neurol. Scand. 2004, 110(4):207-220.
12. Green M.F., Kern R.S., Braff D.L., Mintz J. Neurocognitive deficits and functional outcome in schizophrenia: are we measuring the "right stuff"?. Schizophr. Bull. 2000, 26(1):119-136.
13. Hansen S.S., Munk-Jorgensen P., Guldbaek B., Solgard T., Lauszus K.S., Albrechtsen N., Borg L., Egander A., Faurholdt K., Gilberg A., Gosden N.P., Lorenzen J., Richelsen B., Weischer K., Bertelsen A. Psychoactive substance use diagnoses among psychiatric in-patients. Acta Psychiatr. Scand. 2000, 102(6):432-438.
14. Iqbal M.M., Rahman A., Husain Z., Mahmud S.Z., Ryan W.G., Feldman J.M. Clozapine: a clinical review of adverse effects and management. Ann. Clin. Psychiatry 2003, 15(1):33-48.
15. Kane J., Honigfeld G., Singer J., Meltzer H. Clozapine for the treatment-resistant schizophrenic. A double-blind comparison with chlorpromazine. Arch. Gen. Psychiatry 1988, 45(9):789-796.
16. Karouni M., Arulthas S., Larsson P.G., Rytter E., Johannessen S.I., Johannessen Landmark C. Psychiatric comorbidity in patients with epilepsy: a population-based study. Eur. J. Clin. Pharmacol. 2010, 66:1151-1160.
17. Kavanagh D.J., McGrath J., Saunders J.B., Dore G., Clark D. Substance misuse in patients with schizophrenia: epidemiology and management. Drugs 2002, 62(5):743-755.
18. Kilian R., Becker T., Kruger K., Schmid S., Frasch K. Health behavior in psychiatric in-patients compared with a German general population sample. Acta Psychiatr. Scand. 2006, 114(4):242-248.
19. Kumra S., Schulz S.C. Editorial: research progress in early-onset schizophrenia. Schizophr. Bull. 2008, 34(1):15-17.
20. Leucht S., Burkard T., Henderson J., Maj M., Sartorius N. Physical illness and schizophrenia: a review of the literature. Acta Psychiatr. Scand. 2007, 116(5):317-333.
21. Makikyro T., Karvonen J.T., Hakko H., Nieminen P., Joukamaa M., Isohanni M., Jones P., Jarvelin M.R. Comorbidity of hospital-treated psychiatric and physical disorders with special reference to schizophrenia: a 28year follow-up of the 1966 northern Finland general population birth cohort. Public Health 1998, 112(4):221-228.
22. McGlashan T.H., Fenton W.S. Subtype progression and pathophysiologic deterioration in early schizophrenia. Schizophr. Bull. 1993, 19(1):71-84.
23. Meltzer H.Y. Treatment-resistant schizophrenia - the role of clozapine. Curr. Med. Res. Opin. 1997, 14(1):1-20.
24. Mendez M.F., Grau R., Doss R.C., Taylor J.L. Schizophrenia in epilepsy: seizure and psychosis variables. Neurology 1993, 43(6):1073-1077.
25. Meyer J.M., Stahl S.M. The metabolic syndrome and schizophrenia. Acta Psychiatr. Scand. 2009, 119(1):4-14.
26. Mitchell A.J., Malone D. Physical health and schizophrenia. Curr. Opin. Psychiatry 2006, 19(4):432-437.
27. Munk-Jorgensen P., Mortensen P.B. The Danish psychiatric central register. Dan. Med. Bull. 1997, 44(1):82-84.
28. Nielsen J., Boysen A. Clozapine treatment associated with increased risk of acute myeloid leukemia (AML). Schizophr. Res. 2010, 123(2-3):270-272.
29. Nielsen J., Foldager L., Meyer J.M. Increased use of antibiotics in patients treated with clozapine. Eur. Neuropsychopharmacol. 2009, 19(7):483-486.
30. Nielsen J., Munk-Jorgensen P., Skadhede S., Correll C.U. Determinants of poor dental care in patients with schizophrenia: a historical, prospective database study. J. Clin. Psychiatry 2010, 72:140-143.
31. Nielsen J., Dahm M., Lublin H., Taylor D. Psychiatrists' attitude towards and knowledge of clozapine treatment. J. Psychopharmacol. 2010, 24(7):965-971.
32. Nielsen J., le Quach P., Emborg C., Foldager L., Correll C.U. 10-year trends in the treatment and outcomes of patients with first-episode schizophrenia. Acta Psychiatr. Scand. 2010, 122:356-366.
33. Nielsen J., Skadhede S., Correll C.U. Antipsychotics associated with the development of type 2 diabetes in antipsychotic-naive schizophrenia patients. Neuropsychopharmacology 2010, 35(9):1997-2004.
34. Pedersen C.B., Mortensen P.B. Evidence of a dose-response relationship between urbanicity during upbringing and schizophrenia risk. Arch. Gen. Psychiatry 2001, 58(11):1039-1046.
35. Qin P., Nordentoft M. Suicide risk in relation to psychiatric hospitalization: evidence based on longitudinal registers. Arch. Gen. Psychiatry 2005, 62(4):427-432.
36. Qin P., Xu H., Laursen T.M., Vestergaard M., Mortensen P.B. Risk for schizophrenia and schizophrenia-like psychosis among patients with epilepsy: population based cohort study. BMJ 2005, 331(7507):23.
37. Rabinowitz J., Levine S.Z., Hafner H. A population based elaboration of the role of age of onset on the course of schizophrenia. Schizophr. Res. 2006, 88(1-3):96-101.
38. Rapoport M., Mamdani M., Shulman K.I., Herrmann N., Rochon P.A. Antipsychotic use in the elderly: shifting trends and increasing costs. Int. J. Geriatr. Psychiatry 2005, 20(8):749-753.
39. Sachdev P. Schizophrenia-like psychosis and epilepsy: the status of the association. Am. J. Psychiatry 1998, 155(3):325-336.
40. Saha S., Chant D., McGrath J. A systematic review of mortality in schizophrenia: is the differential mortality gap worsening over time?. Arch. Gen. Psychiatry 2007, 64(10):1123-1131.
41. Smith P.F., Darlington C.L. The development of psychosis in epilepsy: a re-examination of the kindling hypothesis. Behav. Brain Res. 1996, 75(1-2):59-66.
42. Statistics Denmark, (January 18). http://www.dst.dk/Vejviser/Find_Rundt/Emneord/search.aspx?keyword=middellevetid&searchid=1519.
43. Taylor D.M., Young C., Paton C. Prior antipsychotic prescribing in patients currently receiving clozapine: a case note review. J. Clin. Psychiatry 2003, 64(1):30-34.
44. Taylor T.L., Killaspy H., Wright C., Turton P., White S., Kallert T.W., Schuster M., Cervilla J.A., Brangier P., Raboch J., Kalisova L., Onchev G., Dimitrov H., Mezzina R., Wolf K., Wiersma D., Visser E., Kiejna A., Piotrowski P., Ploumpidis D., Gonidakis F., Caldas-de-Almeida J., Cardoso G., King M.B. A systematic review of the international published literature relating to quality of institutional care for people with longer term mental health problems. BMC Psychiatry 2009, 9:55.
45. The Danish National Centre for Social Research, Homelessness in Denmark - National survey, (October 20). http://www.sm.dk/data/Lists/Publikationer/Attachments/398/hjemloeshed_i_danmark.pdf.
46. Tiihonen J., Lonnqvist J., Wahlbeck K., Klaukka T., Niskanen L., Tanskanen A., Haukka J. 11-year follow-up of mortality in patients with schizophrenia: a population-based cohort study (FIN11 study). Lancet 2009, 374(9690):620-627.
47. Trieman N., Leff J. Long-term outcome of long-stay psychiatric in-patients considered unsuitable to live in the community. TAPS Project 44. Br. J. Psychiatry 2002, 181:428-432.
48. Woods S.W. Chlorpromazine equivalent doses for the newer atypical antipsychotics. J. Clin. Psychiatry 2003, 64(6):663-667.
49. The ICD-10 Classification of Mental and Behavioural Disorders: Clinical Descriptions and Diagnostic Guidelines 1992, World Health Organization, World Health Organization, Geneva.
50. Collaborating Centre for Drug Statistics Methodology 2010, World Health Organization, Norwegian Institute of Public Health, (July 27). http://www.whocc.no/atc_ddd_index/.
51. Yood M.U., DeLorenze G., Quesenberry C.P., Oliveria S.A., Tsai A.L., Willey V.J., McQuade R., Newcomer J., L'Italien G. The incidence of diabetes in atypical antipsychotic users differs according to agent-results from a multisite epidemiologic study. Pharmacoepidemiol. Drug Saf. 2009, 18(9):791-799.